10x Genomics Gross Profit

The latest gross profit for TXG is $430M as of June 2026. That compares with $450M in the prior-year period — down 3.5% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside 10x Genomics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TXG's gross profit moved from $450M to $430M — a 3.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 10x Genomics's operating scale or balance-sheet position.

Against Healthcare companies, TXG currently prints $430M for gross profit, while the sector average sits near $65B. That is roughly 99.3% below the sector mean. Large gaps often invite a closer look at 10x Genomics's growth, margins, and balance sheet.

A gross profit figure of $430M for TXG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting TXG's gross profit ($430M), review year-over-year change from $450M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.